News
ARDX
7.39
-0.34%
-0.03
*Ardelyx: Kelliher Served as Group Vice Pres, M&A and Business Development, at Horizon Therapeutics >ARDX
Dow Jones · 3d ago
*Ardelyx Appoints Mike Kelliher, as Executive Vice Pres, Corporate Development and Strategy
Dow Jones · 3d ago
Weekly Report: what happened at ARDX last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at ARDX last week (0311-0315)?
Weekly Report · 03/18 10:27
Ardelyx Shrugs Off 'Mixed' Q4 Earnings
Seeking Alpha · 03/13 22:00
Ardelyx, Inc. Reports Employment Inducement Grants
Ardelyx, Inc. Granted nine new non-executive employees options to purchase shares of the company’s common stock on March 9, 2024. Each stock option has an exercise price equal to $8.69 per share. The company is a biopharmaceutical company.
Barchart · 03/12 15:35
Weekly Report: what happened at ARDX last week (0304-0308)?
Weekly Report · 03/11 10:25
Ardelyx spikes as kidney patient bill advances in Congress
Ardelyx spikes as kidney patient bill advances in Congress. The company's newly launched product, Xphozah, was approved for use in chronic kidney disease patients. The bill's passage removes a key overhang for the company's new product, Jefferies says.
Seeking Alpha · 03/05 20:48
Weekly Report: what happened at ARDX last week (0226-0301)?
Weekly Report · 03/04 10:27
Weekly Report: what happened at ARDX last week (0219-0223)?
Weekly Report · 02/26 10:35
What's Going On With Ardelyx Stock After Earnings?
Ardelyx, Inc. Reported its fourth-quarter financial results after the bell Thursday. The company reported quarterly losses of 12 cents per share and sales of $34.36 million. Shares are moving on above-average trading volume following the company's mixed earnings report.
Benzinga · 02/23 20:37
Where Ardelyx Stands With Analysts
Ardelyx Inc is a biotechnology company focused on the discovery, development and commercialization of drugs. The company has an average price target of $13.0 for the next 12 months. 7 analysts have evaluated ArdelyX in the last three months. The 12-month price targets assessed by analysts reveal a diverse set of opinions on the company.
Benzinga · 02/23 19:00
BUZZ-U.S. STOCKS ON THE MOVE-Hyatt Hotels, Morningstar Inc, SunPower Corp
Wall Street's main indexes lost momentum on Friday. Dow Jones Industrial Average was up 0.28% at 39,179.23. Nvidia Corp briefly vaulted to over $2 trillion in market valuation for the first time. SunPower Corp, Hyatt Hotels, Morningstar Inc were among the biggest losers.
Reuters · 02/23 18:55
Ardelyx Price Target Raised to $15.00/Share From $12.00 by Piper Sandler
Dow Jones · 02/23 18:43
Ardelyx Is Maintained at Overweight by Piper Sandler
Dow Jones · 02/23 18:43
BUZZ-U.S. STOCKS ON THE MOVE-Universal Insurance, Rocket Companies, Legend Biotech
Wall Street's main indexes extended gains on Friday. Nvidia leapt above $2 trillion in market valuation for the first time. Universal Insurance, Rocket Companies, Legend Biotech among the top U.S. Stocks on the move. The Dow Jones Industrial Average was up 0.49% at 39,259.89.
Reuters · 02/23 15:56
Ardelyx Shares Slide After Wider-than-Expected 4Q Loss
Shares of Ardelyx open 7.5% lower at $8.16. The biotechnology company posted a wider fourth-quarter loss than analysts had been projecting. Operating expenses surged as selling, general and administrative costs more than doubled. Shares are still up by about a third from where they started the year.
Dow Jones · 02/23 14:34
BUZZ-U.S. STOCKS ON THE MOVE-Carvana, Plug Power, Live Nation
Wall Street's main indexes were set to open marginally higher on Friday. Nvidia Corp set to top $2 trillion in market value. Carvana, Plug Power, Live Nation are among the top percentage gainers. Dow e-minis were up 0.15% in early trading.
Reuters · 02/23 14:14
Health Care Sector Update for 02/23/2024: ARDX, VCYT, MRVI, XLV, IBB
NASDAQ · 02/23 14:08
Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT), Lantheus (LNTH) and Ardelyx (ARDX)
TipRanks · 02/23 13:40
More
Webull provides a variety of real-time ARDX stock news. You can receive the latest news about Ardelyx through multiple platforms. This information may help you make smarter investment decisions.
About ARDX
Ardelyx, Inc. is a biopharmaceutical company. The Company focuses on discovery, development, and commercialization of advanced medicines that meet significant unmet medical needs. It has two commercial products IBSRELA (tenapanor) and XPHOZAH. Its product pipeline includes RDX013 Program and RDX020 Program. Tenapanor is a small molecule therapy in development for the treatment of or the control of hyperphosphatemia or serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Tenapanor has a mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). IBSRELA is developed for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). XPHOZAH is a medicine for the control of serum phosphorus in adult patients with CKD on dialysis. RDX013 Program is a small molecule potassium secretagogue program for the treatment of hyperkalemia. RDX020 Program is a small molecule for treating metabolic acidosis.